Sotagliflozin ameliorates doxorubicin-induced cardiomyopathy by regulating inflammation and mitochondrial dysfunction through the AMPK/mTOR pathway
Authors:
Open Access
- 4 June 2026
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 32 (2) , 1-18
Abstract
Sodium‑glucose co‑transport protein inhibitor Sotagliflozin (SOTA) has demonstrated cardiovascular benefits in diabetic patients, while doxorubicin (DOX) is widely used to generate cardiomyopathy experimental models. The present study investigated the cardioprotective mechanisms of SOTA on DOX‑induced heart failure in vitro and in vivo. First, C57BL/6 mice were injected with multiple doses of DOX (total 15 mg/kg), and the in vivo impact of SOTA on cardiac function and cardiomyopathy‑related biochemical signaling was assessed. Next, H9C2 cells were treated with DOX in the presence of SOTA to examine the changes in cell viability, mitochondrial function, inflammation, oxidative stress and cell death‑related signal pathways. SOTA treatment in vivo alleviated cardiac dysfunction and fibrosis while reducing cardiomyocyte apoptosis, inflammation, oxidative stress and mitochondrial dysfunction. In vitro, H9c2 cells exposed to DOX in the presence of SOTA exhibited enhanced cell viability and mitigated apoptosis, inflammation, oxidative stress and mitochondrial damage. Furthermore, cleaved caspase‑3 and inflammatory cytokine (IL‑6, IL‑1β and TNF‑α) levels were decreased. Reactive oxygen species and mitochondrial Ca2+ loading were reduced. Mitochondrial dysfunction was also improved, as indicated by increased JC‑1 aggregates and Bcl‑2/Bax ratios. Notably, SOTA activated 5' AMP‑activated protein kinase (AMPK) and inhibited mTOR signaling while protecting from DOX‑induced cardiomyopathy, suggesting SOTA as a promising therapeutic for heart failure treatment.Keywords
This publication has 73 references indexed in Scilit:
- Empagliflozin attenuates DOX-induced cardiotoxicity by inhibiting RIPK1-mediated endoplasmic reticulum stress and autophagyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2025
- SIRT3 attenuates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome via autophagyBiochemical Pharmacology, 2022
- Inflammation suppression in doxorubicin-induced cardiotoxicity: natural compounds as therapeutic optionsNaunyn-Schmiedeberg's Archives of Pharmacology, 2021
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced CardiotoxicityCardiovascular Drugs and Therapy, 2020
- Effect of troxerutin on oxidative stress and expression of genes regulating mitochondrial biogenesis in doxorubicin-induced myocardial injury in ratsNaunyn-Schmiedeberg's Archives of Pharmacology, 2020
- Taurine suppresses doxorubicin-triggered oxidative stress and cardiac apoptosis in rat via up-regulation of PI3-K/Akt and inhibition of p53, p38-JNKBiochemical Pharmacology, 2011
- Does LKB1 Mediate Activation of Hepatic AMP-Protein Kinase (AMPK) and Sirtuin1 (SIRT1) After Roux-en-Y Gastric Bypass in Obese Rats?Journal of Gastrointestinal Surgery, 2009
- Tissue‐specific mtDNA lesions and radical‐associated mitochondrial dysfunction in human hearts exposed to doxorubicinThe Journal of Pathology, 2005
- Caspase inhibitors in prevention of apoptosisHerz, 1999
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993